Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Obu Health vs Queen RX

Obu Health
Graded #332

Lower grade

vs+6.399999999999999
Queen RX
Graded #192

Higher grade

The verdict

Queen RX takes it — 66.3/100 to 59.9/100.

Queen RX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Queen RX offers compounded GLP-1 treatment (semaglutide, tirzepatide, liraglutide) at $299/quarter (~$100/mo).

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueQueen RX +33
44
77
Dose & formulationObu Health +7
64
57
Clinical oversightObu Health +15
84
69
Labs & monitoringEven
53
53
FulfillmentQueen RX +1
74
75
Contract termsQueen RX +30
31
61
Obu Health · left barQueen RX · right bar

The numbers

MetricObu HealthQueen RX
WeighScore59.9/10066.3/100
GradeCC
Scorecard rank#332#192
Semaglutide$190/mo (starting dose, plus a separate fee, compounded)$100/mo (quarterly plan, compounded)
Tirzepatide$239/mo (starting dose, plus a separate fee, compounded)Not disclosed
CoverageCoverage not published45 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Obu Health

Graded #332 · C

Strengths

  • LegitScript-certified with publicly displayed ID (44206977)
  • Two named 503A compounding-pharmacy partners (Manifest Pharmacy SC + RX Compounding Store FL) — transparency above category baseline
  • Lower advertised semaglutide starting price ($190) than most multi-product peer platforms
  • Multi-product offering (GLP-1s + NAD+ + sermorelin + generic ED + birth control) for single-platform users
  • 24-hour US board-certified physician response window

Where it loses points

  • Per-dose pricing tiers not transparently published on product pages — only 'starting from' prices visible
  • No explicit state-coverage list disclosed; FAQ confirms restrictions exist 'based on state' without enumeration
  • Medical director not named publicly
  • No published consultation fee disclosure — unclear whether physician visit is included in medication price
  • All sales final per FAQ ('Federal and State law do not allow medication returns')
Queen RX

Graded #192 · C

Strengths

  • $299/quarter (~$100/mo) — among the lowest GLP-1 pricing in the dataset
  • Three GLP-1 options: semaglutide, tirzepatide, and liraglutide
  • 45-state coverage

Where it loses points

  • No LegitScript or PCAB accreditation
  • No legal entity name or address disclosed
  • No named pharmacy partners
  • Not available in KS, LA, MS, NM, WV

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard